Description

Aromasin（Exemestane）

Exemestane | Steroidal Aromatase Inhibitor | Pharmaceutical Compound

Aromasin（Exemestane） is an irreversible, steroidal aromatase inhibitor that reduces estrogen production by binding to and inactivating the aromatase enzyme. It is an established pharmaceutical compound and is approved for specific breast-cancer indications in postmenopausal women.

Exemestane is also an important compound for endocrine, estrogen-biosynthesis, steroid-metabolism, and pharmacological research.

Key Characteristics

  • Brand Name: Aromasin
  • Active Ingredient: Exemestane
  • Drug Class: Aromatase inhibitor
  • Compound Type: Steroidal / irreversible aromatase inhibitor
  • Common Tablet Strength: 25 mg
  • Primary Target: Aromatase enzyme
  • Research Areas: Estrogen biosynthesis, endocrine signaling, steroid metabolism, and pharmacology

Mechanism of Action

Exemestane acts as a mechanism-based, irreversible inhibitor of aromatase, the enzyme responsible for converting androgens into estrogens.

By reducing aromatase activity, exemestane lowers estrogen production. This makes the compound useful in research examining estrogen-dependent signaling, steroid biosynthesis, endocrine regulation, and aromatase-mediated pathways.

Aromasin Research Applications

Exemestane may be investigated in controlled research involving:

  • Aromatase enzyme inhibition
  • Estrogen biosynthesis
  • Endocrine signaling
  • Steroid metabolism
  • Estrogen-dependent cellular pathways
  • Pharmacokinetic and pharmacodynamic studies
  • Comparative aromatase-inhibitor research
  • Analytical identification and characterization

Research Advantages

Irreversible Aromatase Inhibition

Provides a well-characterized research model for studying irreversible suppression of aromatase activity.

Endocrine Research Utility

Useful for investigating interactions between androgen metabolism, estrogen synthesis, and downstream endocrine signaling.

Steroidal Structure

Its steroidal molecular structure makes it valuable for comparative studies with non-steroidal aromatase inhibitors such as anastrozole.

Analytical Research Compatibility

Suitable for validated analytical methods assessing compound identity, purity, assay, concentration, stability, and degradation.

Pharmaceutical Information

FDA labeling identifies Aromasin as a 25 mg tablet of exemestane. Approved indications include adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer after prior tamoxifen therapy and treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen.

Quality & Documentation

For legitimate analytical or laboratory applications, applicable documentation may include:

  • Active ingredient identity
  • Assay/purity
  • Strength or concentration
  • Batch or lot number
  • Certificate of Analysis (COA)
  • Stability information
  • Relevant analytical test results

Safety & Regulatory Disclaimer

Aromasin（Exemestane）is a pharmacologically active prescription medicine, not a dietary supplement. FDA labeling includes important warnings, including loss of bone mineral density and other clinically significant adverse effects.

This description is intended for scientific, product-identification, and legitimate research/analytical purposes. It does not recommend non-prescribed use or provide dosing instructions. Human use should follow authorized prescribing information and appropriate medical supervision.